Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients

Weigel, Guenter; Griesmacher, Andrea; Karimi, Ali; Zuckermann, Andreas; Grimm, Michael; Mueller, Mathias M.

doi:10.1016/s1053-2498(02)00440-0

Cited by 48 publications

(35 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMF has been reported to reduce B-lymphocyte responses, as patients treated with this agent developed lower antivimentin antibody titers, and this was correlated with the lower incidence of CAV by IVUS (19). In addition, MMF has been reported to reduce the B-lymphocyte count, downregulate activation markers on B-lymphocytes and decrease activation of T-lymphocytes and HLA-DR-expressing natural killer cells (20). MMF has also been reported to decrease systemic inflammatory activity in heart transplant patients as indicated by reduced levels of high-sensitive C-reactive protein (21).…”

Section: Kobashigawa Et Almentioning

confidence: 97%

Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter Trial

Kobashigawa

Tobis

Mentzer

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

The mycophenolate mofetil (MMF) trial involved 650 heart transplant patients from 28 centers who received MMF or azathioprine (AZA), both in combination with cyclosporine and corticosteroids. Baseline and 1-year intravascular ultrasound (IVUS) were performed in 196 patients (102 MMF and 94 AZA) with no differences between groups in IVUS results analyzed by morphometric analysis (average of 10 evenly spaced sites, without matching sites between studies). Baseline to first-year IVUS data can also be analyzed by site-to-site analysis (matching sites between studies), which has been reported to be more clinically relevant. Therefore, we used site-to-site analysis to reanalyze the multicenter MMF IVUS data. Results: IVUS images were reviewed and interpretable in 190 patients (99 MMF and 91 AZA) from the multicenter randomized trial. The AZA group compared to the MMF group had a larger number of patients with first-year maximal intimal thickness (MIT) ≥0.3 mm (43% vs. 23%, p = 0.005), a greater decrease in the mean lumen area (p = 0.02) and a decrease in the mean vessel area (the area actually increased in the MMF group, p = 0.03). Conclusion: MMF-treated heart transplant patients compared to AZA-treated patients, both concurrently on cyclosporine and corticosteroids, in this study have significantly less progression of firstyear intimal thickening.

show abstract

Section: Kobashigawa Et Almentioning

confidence: 97%

Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter Trial

Kobashigawa

Tobis

Mentzer

et al. 2006

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Patients treated with MMF developed lower anti-vimentin antibody titers due to its effect on B lymphocytes, and this correlated with a lower incidence of CAV by IVUS [39]. In addition, MMF decreases activation of T-lymphocytes and HLA-DR-expressing NK cells [40]. MMF may also decrease systemic inflammatory activity in heart transplant patients as indicated by reduced levels of high-sensitivity C-reactive protein [41].…”

Section: Mycophenolatemofetil (Mmf)mentioning

confidence: 99%

Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy

Gupta¹

2014

Cardiol Pharmacol

View full text Add to dashboard Cite

Cardiac allograft vasculopathy (CAV) of heart transplants is responsible for up to one-third of deaths at 5 years following cardiac transplantation. Risk factors for CAV include both traditional risk factors and immune factors. Drugs used for prevention and treatment of CAV include statins, calcium channel blockers and immunosuppressive agents. This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.

show abstract

“…Several studies have demonstrated a decrease in posttransplantation antibody levels, including both anti-HLA and non-HLA antibodies, in heart transplant recipients treated with MMF. 197,198 Weigel et al 199 demonstrated that heart transplant recipients treated with MMF had a significant reduction in B-cell counts compared with healthy control subjects and heart transplant recipients treated with azathioprine. B cells declined at 3 months and were reduced by nearly half at 1 year.…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Colvin¹,

Cook²,

Chang³

et al. 2015

Circulation

287

251

View full text Add to dashboard Cite

Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients

Cited by 48 publications

References 14 publications

Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter Trial

Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter Trial

Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

Contact Info

Product

Resources

About